First Midwest Bank Trust Division purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 68,568 shares of the biopharmaceutical company’s stock, valued at approximately $1,034,000.
Other institutional investors have also recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its holdings in Amicus Therapeutics by 3,672.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock valued at $685,000 after acquiring an additional 66,209 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Amicus Therapeutics by 5.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock worth $5,541,000 after buying an additional 41,711 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Amicus Therapeutics by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock worth $2,073,000 after buying an additional 28,800 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Amicus Therapeutics in the 2nd quarter worth approximately $1,057,000. Finally, Redmile Group LLC raised its holdings in shares of Amicus Therapeutics by 5.9% in the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after buying an additional 668,080 shares in the last quarter.
A number of brokerages have recently issued reports on FOLD. Zacks Investment Research cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 12th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a report on Friday, October 6th. Chardan Capital reissued a “buy” rating and issued a $18.50 target price (up from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Robert W. Baird reissued an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Finally, J P Morgan Chase & Co reissued an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Amicus Therapeutics currently has an average rating of “Buy” and an average price target of $17.81.
In other Amicus Therapeutics news, CEO John F. Crowley sold 449,295 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $14.33, for a total transaction of $6,438,397.35. Following the completion of the transaction, the chief executive officer now directly owns 380,723 shares in the company, valued at $5,455,760.59. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO William D. Baird III sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $570,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 628,224 shares of company stock valued at $9,024,003. 3.40% of the stock is owned by company insiders.
Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) traded down 0.22% during trading on Tuesday, hitting $13.84. The stock had a trading volume of 218,138 shares. The stock’s 50-day moving average is $14.34 and its 200-day moving average is $11.44. The stock’s market capitalization is $2.28 billion. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The company had revenue of $7.16 million during the quarter, compared to the consensus estimate of $6.96 million. During the same period in the previous year, the business earned ($0.40) earnings per share. Analysts predict that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
What are top analysts saying about Amicus Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amicus Therapeutics Inc. and related companies.